Physician profile
Sylvia Wang
NPI 1043254113
$2,964.38
in general payments reported to CMS, 2019-2025
24 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.39 · 2020: $124 · 2021: $482 · 2022: $589 · 2023: $349 · 2024: $679 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $588.82 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $469.26 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $329.07 | 2020-2025 | Breztri, Airsupra, Tezspire |
| Lilly USA, LLC | $313.25 | 2021-2025 | Mounjaro, Ebglyss, Zepbound |
| Novo Nordisk INC | $288.03 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Genzyme Corporation | $179.48 | 2024-2025 | |
| Csl Behring | $108.57 | 2021-2022 | |
| Pfizer INC. | $90.44 | 2023-2025 | |
| Abbott Laboratories | $88.30 | 2022-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $72.46 | 2025 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $56.68 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $55.14 | 2023-2024 | Takhzyro |
| Merck Sharp & Dohme LLC | $48.35 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $46.64 | 2025 | The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $38.73 | 2025 | Ponvory |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $31.55 | 2021 | |
| Pharming Healthcare, INC. | $25.12 | 2024 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $24.48 | 2025 | Neffy |
| Insulet Corporation | $23.48 | 2024 | Omnipod |
| Radius Health, INC. | $20.79 | 2022 | |
| Medtronic, INC. | $19.20 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $17.15 | 2021 | |
| Shire North American Group INC | $15.77 | 2019 | |
| Genentech USA, INC. | $13.62 | 2023 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.